Publication of List of Manufacturers Granted Licence for The Manufacture of Therapeutic Goods - Homart Pharmaceuticals Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply and advertising of therapeutic goods within Australia, aiming to ensure that these products are of acceptable quality, safe, and effective for their intended use. This legislation was introduced to address the need for a comprehensive regulatory framework governing the manufacture, importation, supply, and advertising of therapeutic goods to protect public health and safety. The Act is administered by the Therapeutic Goods Administration, an entity within the Department of Health and Ageing, and its policy objective is to ensure that therapeutic goods available in Australia meet the required standards of quality, safety, and efficacy. The Act encompasses a wide range of therapeutic products, including medicines, medical devices, blood and blood components, and tissues. The publication of the list of manufacturers granted a licence to manufacture therapeutic goods under Section 38 of the Act serves to inform the public and stakeholders of the entities authorised to produce these critical health products.

Scope and Application

The Therapeutic Goods Act 1989 applies to all entities involved in the supply, manufacture, and advertisement of therapeutic goods within Australia. This encompasses a broad range of products, including medicines, medical devices, blood, and tissues, as well as goods related to the administration of therapeutic goods. The Act applies to both individual persons and corporate entities that engage in activities related to therapeutic goods, ensuring that these goods meet safety, quality, and efficacy standards before they are made available in the market. The Act's jurisdiction extends across the Commonwealth, and it applies to all states and territories within Australia, thereby establishing a uniform regulatory framework for therapeutic goods nationwide. While the Act broadly applies to the therapeutic goods industry, it does include specific exclusions and exemptions, such as certain types of goods used for personal, non-commercial purposes. The application and enforcement of the Act can be extended or restricted through subordinate instruments, such as regulations and guidelines, which provide further detail on specific aspects of the legislation.

Key Provisions

The Therapeutic Goods Act 1989 includes several key provisions that pertain to the regulation and oversight of therapeutic goods in Australia. Section 38 of the Act allows the Secretary of the Department of Health and Ageing, through the Therapeutic Goods Administration (TGA), to grant a licence to a person for the manufacture of therapeutic goods (section 38). This section specifies that a written notice must be issued to the manufacturer, indicating that they have been granted a licence. This licence permits the holder to legally manufacture therapeutic goods within the parameters set by the TGA. The obligations imposed by the Act on the parties or entities it governs are comprehensive. Manufacturers who hold a licence under Section 38 must adhere to stringent standards and requirements to ensure that the therapeutic goods they produce are safe, of high quality, and effective. These obligations include maintaining detailed records of their manufacturing processes, ensuring that their facilities meet the necessary standards for cleanliness and safety, and complying with any other conditions specified in their licence. Manufacturers must also notify the TGA of any changes to their manufacturing processes, premises, or personnel that might affect the quality and safety of the therapeutic goods they produce. Breaching the provisions of the Therapeutic Goods Act 1989 can result in serious consequences. Offences under the Act can lead to both civil and criminal penalties. For instance, knowingly manufacturing or supplying therapeutic goods that do not meet the standards set by the TGA can result in significant fines and even imprisonment. The maximum penalties for these offences can be substantial, reflecting the importance of ensuring that therapeutic goods are safe and effective for consumers. Failure to comply with the Act's requirements can also result in the revocation of a manufacturer's licence, effectively shutting down their operations and potentially leading to legal action. The specific penalties depend on the nature and severity of the breach, but they are designed to enforce strict compliance with the Act's provisions.